Ionis Capital Lease Obligations from 2010 to 2025
IONS Stock | USD 32.32 0.37 1.13% |
Capital Lease Obligations | First Reported 2010-12-31 | Previous Quarter 161.8 M | Current Value 110.6 M | Quarterly Volatility 55.9 M |
Check Ionis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ionis Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 27.2 M, Interest Expense of 88.6 M or Total Revenue of 740.4 M, as well as many indicators such as Price To Sales Ratio of 7.04, Dividend Yield of 0.0 or PTB Ratio of 8.44. Ionis financial statements analysis is a perfect complement when working with Ionis Pharmaceuticals Valuation or Volatility modules.
Ionis | Capital Lease Obligations |
Latest Ionis Pharmaceuticals' Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Ionis Pharmaceuticals over the last few years. Ionis Pharmaceuticals capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Ionis Pharmaceuticals asset purchases. For example, Ionis Pharmaceuticals can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Ionis Pharmaceuticals control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Ionis Pharmaceuticals' Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ionis Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
Timeline |
Ionis Capital Lease Obligations Regression Statistics
Arithmetic Mean | 75,405,471 | |
Geometric Mean | 0.00 | |
Coefficient Of Variation | 74.09 | |
Mean Deviation | 40,078,081 | |
Median | 72,359,000 | |
Standard Deviation | 55,870,349 | |
Sample Variance | 3121.5T | |
Range | 178.9M | |
R-Value | 0.38 | |
Mean Square Error | 2870.1T | |
R-Squared | 0.14 | |
Significance | 0.15 | |
Slope | 4,419,466 | |
Total Sum of Squares | 46822.4T |
Ionis Capital Lease Obligations History
About Ionis Pharmaceuticals Financial Statements
Ionis Pharmaceuticals shareholders use historical fundamental indicators, such as Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Although Ionis Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Ionis Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Ionis Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last Reported | Projected for Next Year | ||
Capital Lease Obligations | 161.8 M | 110.6 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.